epivaccorona
VaccineexperimentalCOVID-19
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 27, 2020 (NCT04527575)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05021016 | Phase 3 | Nov 19, 2020 | Burnasyan Federal Medical Biophysical Center, Government of Russia |
| NCT04780035 | Phase 3 | Nov 18, 2020 | Government of Russia, Immanuel Kant Baltic University, Kazan State Medical University, Pirogov Russian National Research Medical University |
| NCT04527575 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2020 | Burnasyan Federal Medical Biophysical Center, Government of Russia |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Russia | Government | 3 | 3 | 2 | 2020 |
| Burnasyan Federal Medical Biophysical Center | Government | 2 | 0 | 2 | 2020 |
| Immanuel Kant Baltic University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Kazan State Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Pirogov Russian National Research Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1